Improved quality control of [177Lu]Lu-PSMA I&T

被引：0
作者：
Martin Kraihammer
Piotr Garnuszek
Andreas Bauman
Michael Maurin
Manuel Alejandre Lafont
Roland Haubner
Elisabeth von Guggenberg
Michael Gabriel
Clemens Decristoforo
机构：
[1] Medical University Innsbruck,Department of Nuclear Medicine
[2] Kepler University Hospital,Department of Nuclear Medicine and Endocrinology
[3] National Centre for Nuclear Research,Radioisotope Centre POLATOM
[4] University Hospital Basel,Division of Radiopharmaceutical Chemistry
来源：
EJNMMI Radiopharmacy and Chemistry | / 8卷
关键词：
PSMA; [; Lu]Lu-PSMA I&T; Zadavotide guraxetan; Radionuclide therapy; Quality control; HPLC; TLC; Validation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Factors affecting overall survival and progression-free survival in patients with metastatic castration resistant prostate cancer received 177Lu PSMA I&T therapy
    Bulbul, Ogun
    Unek, Ilkay Tugba
    Kefi, Aykut
    Tuna, Emine Burcin
    Bekis, Recep
    HELLENIC JOURNAL OF NUCLEAR MEDICINE, 2020, 23 (03) : 229 - 239
  • [32] [68Ga]Ga-PSMA PET/MRI, histological PSMA expression and preliminary experience with [177Lu]Lu-PSMA therapy in relapsing high-grade glioma
    Truckenmueller, Peter
    Graef, Josefine
    Scheel, Michael
    Vajkoczy, Peter
    Capper, David
    Kaul, David
    Furth, Christian
    Amthauer, Holger
    Brenner, Winfried
    Onken, Julia Sophie
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [33] Response to [177Lu]Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients presenting with only lymph node metastases
    Zisser, Lucia
    Yu, Josef
    Oszwald, Andre
    Wollenweber, Tim
    Kretschmer-Chott, Elisabeth
    Grubmueller, Bernhard
    Kramer, Gero
    Shariat, Shahrokh F.
    Mitterhauser, Markus
    Vraka, Chrysoula
    Hacker, Marcus
    Haug, Alexander R.
    Rasul, Sazan
    NUCLEAR MEDICINE COMMUNICATIONS, 2022, 43 (11) : 1113 - 1120
  • [34] Automatic bone marrow segmentation for precise [177Lu]Lu-PSMA-617 dosimetry
    Lu, Zhonglin
    Hu, Jiaxi
    Chen, Gefei
    Jiang, Han
    Shih, Cheng-Ting
    Afshar-Oromieh, Ali
    Rominger, Axel
    Shi, Kuangyu
    Mok, Greta S. P.
    MEDICAL PHYSICS, 2025,
  • [35] Towards fully automatized [177Lu]Lu-PSMA personalized dosimetry based on 360° CZT whole-body SPECT/CT: a proof-of-concept
    Dieudonne, Arnaud
    Terro, Aya
    Dumouchel, Arthur
    Perret, Solene
    Edet-Sanson, Agathe
    Vera, Pierre
    Hapdey, Sebastien
    Modzelewski, Romain
    Tonnelet, David
    Decazes, Pierre
    EJNMMI PHYSICS, 2025, 12 (01):
  • [36] Quality Assurance Investigations and Impurity Characterization during Upscaling of [177Lu]Lu-PSMAI&T
    Schmitl, Stefan
    Raitanen, Julia
    Witoszynskyj, Stephan
    Patronas, Eva-Maria
    Nics, Lukas
    Ozenil, Marius
    Weissenboeck, Victoria
    Mindt, Thomas L.
    Hacker, Marcus
    Wadsak, Wolfgang
    Brandt, Marie R.
    Mitterhauser, Markus
    MOLECULES, 2023, 28 (23):
  • [37] Quantification of biochemical PSA dynamics after radioligand therapy with [177Lu]Lu-PSMA-I&T using a population pharmacokinetic/pharmacodynamic model
    Siebinga, Hinke
    de van der Veen, Berlinda J.
    de Vries-Huizing, Daphne M. V.
    Vogel, Wouter V.
    Hendrikx, Jeroen J. M. A.
    Huitema, Alwin D. R.
    EJNMMI PHYSICS, 2024, 11 (01)
  • [38] Prostate-Specific Membrane Antigen Radioligand Therapy Using 177Lu-PSMA I&T and 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: Comparison of Safety, Biodistribution, and Dosimetry
    Schuchardt, Christiane
    Zhang, Jingjing
    Kulkarni, Harshad R.
    Chen, Xiaoyuan
    Mueller, Dirk
    Baum, Richard P.
    JOURNAL OF NUCLEAR MEDICINE, 2022, 63 (08) : 1199 - 1207
  • [39] Outcome and safety of rechallenge [177Lu]Lu-PSMA-617 in patients with metastatic prostate cancer
    Anna Yordanova
    Paula Linden
    Stefan Hauser
    Michael Meisenheimer
    Stefan Kürpig
    Georg Feldmann
    Florian C. Gaertner
    Markus Essler
    Hojjat Ahmadzadehfar
    European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46 : 1073 - 1080
  • [40] Outcome and safety of rechallenge [177Lu]Lu-PSMA-617 in patients with metastatic prostate cancer
    Yordanova, Anna
    Linden, Paula
    Hauser, Stefan
    Meisenheimer, Michael
    Kuerpig, Stefan
    Feldmann, Georg
    Gaertner, Florian C.
    Essler, Markus
    Ahmadzadehfar, Hojjat
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (05) : 1073 - 1080
12345